METTL3 and acute myeloid leukemia: In this study, we report the development of AF151 (compound 41), a potent METTL3 degrader with an indole-nicotinamide METTL3 binding chemotype based on a series of METTL3 ligands developed by STORM Therapeutics16 and EPICS Therapeutics.18AF151 exhibits efficient METTL3 degradation and reduces viability in AML cells, offering a structurally distinct alternative to previously reported UZH2-based PROTACs.